This is a a randomized double blind placebo controlled Phase 2 trial with a 12 patient
lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a
total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill
patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard
of care plus Decitabine or standard of care plus saline based placebo. The primary objective
is to determine safety and efficacy of decitabine for COVID-19 ARDS based on clinical
improvement on a 6-point clinical scale.